The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,301 GBX | -0.83% | +1.68% | +16.17% |
02:06pm | Innate Pharma: five abstracts selected for ASCO | CF |
02:07am | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.
The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+16.17% | 244B | |
+38.49% | 728B | |
+32.73% | 603B | |
-5.06% | 360B | |
+20.19% | 332B | |
+1.96% | 279B | |
+8.05% | 207B | |
-5.52% | 205B | |
+6.15% | 164B | |
+0.07% | 122B |